ReviewCells2023
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 31 citations in OpenAlex.
- Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?World journal of gastroenterology · 2024Trial
- Advancing therapeutic frontiers: a pipeline of novel drugs for UC management.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- A Randomized Double-Blind, Placebo-Controlled Trial of Artesunate and Curcumin in Patients With Crohn's Disease: A Pilot Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Intestinal Fibrosis in Crohn's Disease: Pathophysiology, Diagnosis, and New Therapeutic Targets.Journal of clinical medicine · 2025Review
- Interaction between 3-SNP genetic risk score and dietary fats intake on inflammatory markers among overweight and obese women.Journal of diabetes and metabolic disorders · 2025Article
- Right-Sided Dysplasia in Inflammatory Bowel Disease Is Not Associated with Conventional Risk Factors for Neoplasia.Gastroenterology insights · 2025Article
- Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.Advances in therapy · 2025Review
- An Assessment of the Nutritional Status in Patients with Inflammatory Bowel Disease-A Matched-Pair Case-Control Study.Nutrients · 2025Article
- Cholangioscope-assisted ERAT for the diagnoses and treatment of ulcerative colitis with appendiceal orifice inflammation: a case report and a literature review.International journal of colorectal disease · 2025Review
- Distinct Profiles of Fecal Volatile Organic Compounds Discriminate Ulcerative Colitis Patients With an Ileoanal Pouch From Those With an Intact Colon.Molecular nutrition & food research · 2025Article
- Serum Maresin-1 and Resolvin-D1 Levels as Non-Invasive Biomarkers for Monitoring Disease Activity in Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2025Article
- Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Research Status and Trends of Gut Microbiota and Intestinal Diseases Based on Bibliometrics.Microorganisms · 2025Article
- Inflammatory Bowel Disease from the Perspective of Newer Innate Immune System Biomarkers.Gastrointestinal disorders (Basel, Switzerland) · 2025Article
- Irritable bowel syndrome remains a complex disorder of gut-brain interaction: Too many actors on stage.World journal of gastroenterology · 2025Article
- Hyperbaric Oxygen Therapy in the Treatment of Crohn's Disease.Healthcare (Basel, Switzerland) · 2025Article
- Natural products for the treatment of ulcerative colitis: focus on the JAK/STAT pathway.Frontiers in immunology · 2025Review
- α-Methyl-Tryptophan Inhibits SLC6A14 Expression and Exhibits Immunomodulatory Effects in Crohn's Disease.Journal of inflammation research · 2025Article
- Metformin Ameliorates Ulcerative Colitis Through Inhibiting NLRP3 Inflammasome Activation.Journal of inflammation research · 2025Article
- Association Between Caffeine Intake and Bowel Habits and Inflammatory Bowel Disease: A Population-Based Study.Journal of multidisciplinary healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The melanocortin system is a complex set of molecular mediators and receptors involved in many physiological and homeostatic processes. These include the regulation of melanogenesis, steroidogenesis, neuromodulation and the modulation of inflammatory processes. In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis. Indeed, information on how such a system can counteract colitis inflammation and intervene in the complex cytokine imbalance in the intestinal microenvironment affected by chronic inflammatory damage has emerged. This review summarises the evidence acquired so far and highlights that molecules interfering with the melanocortin system could represent new drugs for treating IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.